 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ASKG315 / Aosaikang Pharma
Trial initiation date, Combination therapy, Metastases: A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 14, 2023
P1, N=100, Not yet recruiting, Sponsor: AskGene Pharma, Inc.
Initiation date: Sep 2022 --> Aug 2023
- ||| ASKG315 / Aosaikang Pharma
Enrollment open, Trial primary completion date, Metastases: A Study of ASKG315 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - Mar 1, 2023
P1, N=56, Recruiting, Sponsor: AskGene Pharma, Inc.
Initiation date: Sep 2022 --> Aug 2023 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2023 --> Dec 2023
- || ASKG315 / Aosaikang Pharma, ASKG915 / Aosaikang Pharma
#AskGene Presents Latest Results on #ASKG315 and #ASKG915 at #SITC22 https://t.co/srKNP2Y4tE (Twitter) - Nov 16, 2022
- ASKG315 / Aosaikang Pharma
ASKG315 - An IL-15 Prodrug with Antibody-Like PK, Enhanced Safety and Expanded Therapeutic Window (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1409;
A first-in-human (FIH) study for ASKG315 is expected to start in the second half of 2022. Ethics Approval The uses of the animals in the in vivo studies were approved by the ethics committees of the CROs who performed the studies.
- ||| ASKG315 / Aosaikang Pharma
New P1 trial, Metastases: A Study of ASKG315 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - Sep 26, 2022
P1, N=56, Not yet recruiting, Sponsor: AskGene Pharma, Inc.
- ||| ASKG315 / Aosaikang Pharma
New P1 trial, Combination therapy, Metastases: A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 22, 2022
P1, N=100, Not yet recruiting, Sponsor: AskGene Pharma, Inc.